Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475955 · ClinicalTrials.gov registry record · Phase 2
Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)
A Phase 2 study, sponsored by DUSA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 235
- Enrollment target
NCT01475955 is a Phase 2 study that has completed, run by DUSA Pharmaceuticals. The registered enrollment target is 235 participants.
The verdict
NCT01475955, a Phase 2 study, has completed, sponsored by DUSA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 235 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.
Interventions
- DRUG Broad Area ALA 1-hour incubation
- DRUG Broad Area ALA 2 hour incubation
- DRUG broad area ALA 3-hour incubation
- DRUG Spot ALA 2 hour incubation
- DRUG Vehicle PDT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 235 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475955
The ClinicalTrials.gov registry entry for NCT01475955 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 235 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DUSA Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Broad Area ALA 1-hour incubation is the first listed.
NCT01475955 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475955 about?
NCT01475955 is a clinical study titled "Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)". The purpose of this study is to determine if Levulan Photodynamic Therapy (PDT) is safe and effective in the treatment of actinic keratosis when applied to broad areas on the face and scalp for 1, 2 and 3 hours.
What is the current status of trial NCT01475955?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 235 participants. The study started on 2011-12. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01475955?
The interventions under investigation include: Broad Area ALA 1-hour incubation (DRUG), Broad Area ALA 2 hour incubation (DRUG), broad area ALA 3-hour incubation (DRUG), Spot ALA 2 hour incubation (DRUG), Vehicle PDT (DRUG).
Who is sponsoring clinical trial NCT01475955?
This trial is sponsored by DUSA Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.